Literature DB >> 17037945

Clinical trials research in pediatrics: strategies for effective collaboration between investigator sites and the pharmaceutical industry.

Andrew Bush1.   

Abstract

There is a paucity of clinical trials work in children, which leads to the frequent use of off-label and unlicensed medications in this very vulnerable group. Clinical trials work in children may be more difficult than in adults, and there are certainly ethical constraints. However, the differences between adults and children, and at different stages of childhood development, mandate strategies to improve this situation rather than continually relying on extrapolation from adult studies. Therefore, new strategies have to be established between the pharmaceutical industry and pediatric centers to facilitate effective trials work. These must be based on a clear and mutual understanding of the differences between working with children and adults. Disease phenotypes may be completely different in children; for example, wheeze in infants is not miniature adult asthma. Clinical trial design must be practical, and a trial is more likely to succeed if a simple design is utilized, with minimal interference with school work and the work of carers. The new UK initiative, 'Medicines for Children', should go a long way towards addressing the problem, and increase the evidence base for the utilization of medications in pediatric practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17037945     DOI: 10.2165/00148581-200608050-00001

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  48 in total

Review 1.  Increasing response rates to postal questionnaires: systematic review.

Authors:  Phil Edwards; Ian Roberts; Mike Clarke; Carolyn DiGuiseppi; Sarah Pratap; Reinhard Wentz; Irene Kwan
Journal:  BMJ       Date:  2002-05-18

2.  Paediatric research should take centre stage.

Authors: 
Journal:  Lancet       Date:  2004 Aug 28-Sep 3       Impact factor: 79.321

3.  Asthma drug adherence in a long term clinical trial.

Authors:  G Jónasson; K H Carlsen; P Mowinckel
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

4.  Poor inhalation technique, even after inhalation instructions, in children with asthma.

Authors:  A W Kamps; B van Ewijk; R J Roorda; P L Brand
Journal:  Pediatr Pulmonol       Date:  2000-01

5.  Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants.

Authors:  S M Stick; P R Burton; L Gurrin; P D Sly; P N LeSouëf
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

6.  Pulmonary function at school-age in surfactant-treated preterm infants.

Authors:  M Gappa; M M Berner; S Hohenschild; C E Dammann; P Bartmann
Journal:  Pediatr Pulmonol       Date:  1999-03

7.  Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.

Authors:  R T Stein; D Sherrill; W J Morgan; C J Holberg; M Halonen; L M Taussig; A L Wright; F D Martinez
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

8.  Lung deposition of inhaled drugs increases with age.

Authors:  J Onhøj; L Thorsson; H Bisgaard
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

9.  Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study.

Authors:  S Turner; A J Nunn; K Fielding; I Choonara
Journal:  Acta Paediatr       Date:  1999-09       Impact factor: 2.299

10.  Issues surrounding the participation of adolescents with cancer in clinical trials in the UK.

Authors:  A McTiernan
Journal:  Eur J Cancer Care (Engl)       Date:  2003-09       Impact factor: 2.520

View more
  1 in total

1.  A Delphi process to optimize quality and performance of drug evaluation in neonates.

Authors:  Frederic Legrand; Rym Boulkedid; Valery Elie; Stephanie Leroux; Elizabeth Valls; Adolfo Valls-i-Soler; Johannes N Van den Anker; Evelyne Jacqz-Aigrain
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.